Navigation Links
Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
Date:11/12/2009

CORAL GABLES, Fla., Nov. 12 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) today reported financial results for the third quarter and nine months ended September 30, 2009.

Third Quarter 2009 Results

For the quarter ended September 30, 2009, the Company reported a net loss of $1,286,720, or $0.09 per basic and diluted share, compared to a net loss of $2,855,360, or $0.22 per basic and diluted share for the same period in 2008. Third quarter 2009 results included non-cash charges relating to stock-based compensation in the amount of $75,355, compared to $104,565 in the same period in 2008. For the nine months ended September 30, 2009, the Company reported a net loss of $6,079,808, or $0.43 loss per basic and diluted share, compared to a net loss of $6,816,847, or $0.54 loss per basic and diluted share, for the same period in 2008. Results for the first nine months of 2009 included non-cash charges relating to stock-based compensation in the amount of $282,161, compared to $491,177 in the same period in 2008.

Research and development expenses for the third quarter of 2009 were $850,998 compared to $2,451,579 in the third quarter of 2008, including non-cash stock-based compensation of $42,642 and $54,476, respectively. Research and development expenses for the nine months ended September 30, 2009 were $4,549,883 compared to $5,438,082 for the first nine months of 2008, including non-cash stock-based compensation of $162,782 and $328,564, respectively.

General and administrative expenses for the third quarter of 2009 totaled $441,316 compared to $463,199 for the third quarter of 2008, including non-cash stock-based compensation of $32,713 and $50,089, respectively. General and administrative expenses for the first nine months of 2009 totaled $1,555,786 compared to $1,664,405 in the first nine months of 2008, including non-cash stock-based compensation of $119,379 and
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
10. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
11. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013   Accuray Incorporated (Nasdaq: ... is scheduled to present at the 2013 Jefferies Global ... on Thursday, June 6, 2013 at 1:30 p.m. EDT/10:30 ... presentation will be available online from the Investor Relations ... The webcast replay of the presentation will begin ...
(Date:5/22/2013)... 2013  The Leukemia & Lymphoma Society (LLS) is ... LLC, a joint venture between ImmunGene and Caliber, to ... Phase I clinical trial for a novel fusion protein ... patients with indolent lymphomas who do not respond to ... IGN002, is a new class of biotherapeutics produced by ...
(Date:5/22/2013)... and MUNICH , May 22, ... manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems ... first interim results of the J enaValve Eval U ... I n Pa T ients with S E vere Ao ... Paris . JUPITER is a post-market registry to evaluate ...
Breaking Medicine Technology:The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4
... July 14 D3 Radiation Services announced today  that the ... reduce errors in the delivery of radiation therapy--as a Practice Quality Improvement ... , , ... radiation oncology physicists can order a comprehensive audit of their beam data ...
... 14 Mylan Inc. (Nasdaq: MYL ) ... received final approval from the U.S. Food and Drug ... for Nabumetone Tablets USP, 500 mg and 750 mg. ... therapeutically equivalent to Nabumetone Tablets, a treatment for osteoarthritis ...
Cached Medicine Technology:eDataAudit Receives Approval from the American Board of Radiology 2Mylan Receives Approval for Nabumetone Tablets 2
(Date:5/22/2013)... News) -- Over the next two decades, the cost ... to more than double, topping more than $180 billion ... factor driving the increase: an aging population. The report, ... Stroke Association, was published May 22 in the journal ... health care system," Dr. Bruce Ovbiagele, chairman of the ...
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay ... great deal of suffering, but new research indicates the ... else entirely -- a smaller brain. , , Already ... of depression, scientists wanted to determine if having both ... size -- about 2 percent -- isn,t alarming, study ...
(Date:5/22/2013)... Johns Hopkins researchers report that hospitals may be ... are complicated by preventable bloodstream infections contracted in ... new study, reported online in the American ... that an ICU patient who develops an avoidable ... times more to care for than a similar ...
(Date:5/22/2013)... 22, 2013 Award Presented at the ... press release here: http://bit.ly/13DkFfk , Merrill Corporation ... “Information Management Product/Service of the Year” at the 7th ... The Colony Hotel in Palm Beach, Florida. , ... room (VDR) solution that optimizes the due diligence ...
(Date:5/22/2013)... 22, 2013 Phelps Memorial Hospital Center ... Westchester Lung Nodule Center for individuals who would like ... care. Lung cancer is the deadliest form of cancer for ... the U.S. die from lung cancer than from breast, colon ... early detection increases survival rates. It is well established ...
Breaking Medicine News(10 mins):Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3Health News:Having Both Migraines, Depression May Mean Smaller Brain 2Health News:Having Both Migraines, Depression May Mean Smaller Brain 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3
... Recent study reports that women don’t have to worry about their ... fertility is higher only in their thirties. // Women don’t have ... be a constraint for conception of babies. Researchers have found from ... as man as increased considerably. The fertility rate of women in ...
... as formed a new cabinet committee to plan strategies to ... has said that though the United Kingdom //Government has taken ... flu spread but the committee feels still a lot has ... ,The committee feels that the Government should organize the food ...
... Motion has been developed by University of Toronto scientists with ... again. The device makes the muscles// work again by sending ... called functional electrical stimulation or FES, is unlike similar therapies ... is not dependent on the machine. ,Instead, the ...
... it takes to get pregnant or conceive the sex of the ... by Dutch reserachers. //The sample size was 5,283 women who gave ... ,Among the 498 women who took longer than 12 months ... whereas the proportion of male births among the 4,785 women with ...
... UK Parliamentarian Roger Williams has called for a ban ... the production of 6,000 types of medicines, food and ... the sweetener, which is used in cereal, chocolate and ... published reports that aspartame caused cancer in rats. Doses ...
... the Government in treating drug addicts is beginning to yield ... users seeking treatment in 2004. Heroin users accounted for 8,000 ... the number of people trying to get back to normal ... the figures, which also said that the percentage of heroin ...
Cached Medicine News:
Straight, with guard. Ideal for multi-directional manipulation....
Vaulted shank with guard....
Vaulted shank. For engaging the inferior haptic without touching the dome of the IOL....
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
Medicine Products: